essence semaglutide phase 3 trial of showed significant improvements at 72 weeks in adults with MASH, published in NEJM essence semaglutide Phase 3 Trial:

The FDA approved semaglutide under the brand name Wegovy specifically for chronic weight management in 2021

Weekly Administration During Intermediate Phase After the first phase, injections are given weekly for four to eight weeks

Stone EM, Glazer ES, Chantranupong L, Cherukuri P, Breece RM, Tierney DL, Curley SA, Iverson BL, Georgiou G

Glucagon-like peptide-1 (GLP-1), an incretin secreted by L-cells lining the gastrointestinal epithelium, has important functions: promoting insulin secretion, insulin sensitivity, and -cell mass, while inhibiting gastric emptying and appetite

Novel therapeutic delivery of Nanocurcumin in central nervous system related disorders